Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight

The vasomotor symptoms market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, aging demographics, increased awareness, the launch of emerging therapies such as Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga Pharmaceuticals), ABCL635 (AbCellera Biologics), Refisolone (PH80; Vistagen Therapeutics), and others, and healthcare spending across the 7MM.

LAS VEGAS, Sept. 30, 2026 /PRNewswire/ -- Recently published Vasomotor Symptoms Market Insights report includes a comprehensive understanding of current treatment practices, vasomotor symptoms emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Vasomotor Symptoms Market Summary

• The total vasomotor symptoms treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest vasomotor symptoms treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In the US, the estimated prevalence of vasomotor symptoms is ~46% during the early menopausal transition and increases to 60–80% across the menopausal transition and postmenopausal period.
• Leading vasomotor symptoms companies, such as Noema Pharma, Tioga Pharmaceuticals, AbCellera Biologics, Vistagen Therapeutics, MenoGeniX, Fervent Pharmaceuticals, and others, are developing new vasomotor symptoms treatment drugs that can be available in the vasomotor symptoms market in the coming years. 
• The promising vasomotor symptoms therapies in clinical trials include Cendifensine (NOE-115), Asimadoline, ABCL635, Refisolone (PH80), MNGX-100, FP-101, and others.

Discover the menopause-related vasomotor symptoms market @ https://www.delveinsight.com/report-store/vasomotor-symptoms-market

Key Factors Driving the Growth of the Vasomotor Symptoms Market 

• Rising Prevalence of Menopausal Symptoms: A growing number of women are experiencing menopause-related vasomotor symptoms (VMS), including hot flashes and night sweats. The increasing prevalence of these symptoms is expanding the addressable patient population and driving demand for effective treatment options.
• Growing Awareness of Menopause Management: Greater awareness of menopause and its impact on quality of life is encouraging women to seek medical advice and treatment. Improved education among patients and healthcare professionals is also supporting earlier diagnosis and management of VMS.
• Increasing Demand for Non-Hormonal Therapies: Concerns regarding the safety and suitability of hormone-based treatments are increasing interest in non-hormonal alternatives. This is creating opportunities for novel therapies that can effectively manage VMS without relying on estrogen or other hormonal agents.
• Advancements in Targeted Therapeutics: Growing understanding of the neurobiological mechanisms underlying hot flashes is facilitating the development of targeted therapies. New approaches aimed at modulating pathways involved in thermoregulation are broadening the treatment landscape.
• Introduction of Novel Mechanism-Based Treatments: The emergence of therapies such as Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga Pharmaceuticals), ABCL635 (AbCellera Biologics), Refisolone (PH80; Vistagen Therapeutics), MNGX-100 (MenoGeniX), FP-101 (Fervent Pharmaceuticals), and others with differentiated mechanisms of action is expected to strengthen competition and expand treatment choices. 

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging assets such as cendifensine (NOE-115) and asimadoline (TP0052) may expand future treatment options through novel mechanisms; however, their adoption will depend on clinical efficacy, safety, regulatory approval, and differentiation from currently available therapies.

Vasomotor Symptoms Market Analysis

• The current treatment paradigm follows a multi-tiered approach that includes lifestyle modifications, over-the-counter (OTC) remedies, hormonal therapies, and non-hormonal pharmacological interventions. 
• Hormone therapy, consisting of estrogen alone or in combination with progestogens, remains a highly effective treatment option for eligible women. 
• However, non-hormonal approaches are increasingly being adopted among patients who have contraindications to hormone therapy or prefer to avoid hormonal treatments.
• Despite the availability of multiple treatment options, substantial unmet needs persist due to contraindications associated with hormone therapy, inconsistent treatment responses, safety considerations, and growing patient preference for non-hormonal alternatives. These limitations have driven increasing demand for therapies with novel non-hormonal mechanisms of action.
• The treatment landscape has recently evolved with the introduction of targeted non-hormonal therapies, most notably fezolinetant (VEOZAH, Astellas Pharma), as well as bazedoxifene acetate/conjugated estrogens (DUAVEE, Pfizer) and other emerging approaches.
• Beyond approved therapies, several investigational agents are advancing through clinical development, highlighting continued innovation across non-hormonal and neuroendocrine treatment pathways. Key investigational compounds include asimadoline (Tioga Pharmaceuticals), cendifensine (Noema Pharma), and others.
• Overall, the treatment landscape for vasomotor symptoms is undergoing a notable transition toward non-hormonal, CNS-targeted therapies. 
• This shift is being driven by the limitations and contraindications associated with hormone-based treatment, persistent unmet needs in symptom management, and growing scientific interest in hypothalamic thermoregulatory pathways as central therapeutic targets.

Vasomotor Symptoms Competitive Landscape

Some of the vasomotor symptoms drugs under development include Cendifensine (NOE-115; Noema Pharma), Asimadoline (Tioga Pharmaceuticals), ABCL635 (AbCellera Biologics), Refisolone (PH80; Vistagen Therapeutics), MNGX-100 (MenoGeniX), FP-101 (Fervent Pharmaceuticals), and others. 

Noema Pharma's Cendifensine (NOE-115) is an investigational, non-hormonal therapy being developed by Noema Pharma for the treatment of menopausal vasomotor symptoms (VMS). It is an oral, once-daily, broad-spectrum monoamine modulator designed to influence monoaminergic pathways involved in thermoregulation and the management of menopausal symptoms.

Cendifensine is currently being evaluated in a Phase II clinical study in women experiencing moderate-to-severe VMS, including hot flashes and night sweats. The asset offers a novel non-hormonal treatment approach, with potential differentiation based on its broad monoamine modulation mechanism compared with more targeted therapies.

Tioga Pharmaceuticals' Asimadoline (TP0052) is an investigational non-hormonal therapy being developed by Tioga Pharmaceuticals for the treatment of menopausal vasomotor symptoms. It is a peripherally restricted, selective kappa opioid receptor agonist designed to modulate peripheral sensory and autonomic pathways involved in thermoregulation and the control of menopausal symptoms.

The asset is currently being evaluated in a Phase II clinical study designed to assess its safety and efficacy in women with moderate-to-severe menopausal vasomotor symptoms.

AbCellera Biologics' ABCL635 is an investigational, first-in-class antibody therapy being developed as a non-hormonal treatment for menopause-associated VMS, commonly referred to as hot flashes. The therapy selectively targets the neurokinin 3 receptor (NK3R), a clinically validated membrane protein expressed on KNDy neurons in the infundibular nucleus of the hypothalamus, which plays an important role in regulating body temperature.

ABCL635 is the first AbCellera-led program generated through the company's GPCR and ion channel technology platforms. It is currently being evaluated in a Phase I/II clinical trial to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and the frequency and severity of VMS following subcutaneous administration of ABCL635.

The anticipated launch of these emerging therapies are poised to transform the vasomotor symptoms market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the vasomotor symptoms market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the vasomotor symptoms treatment @ Vasomotor Symptoms Treatment Market

Recent Developments in the Vasomotor Symptoms Market

• In August 2026, Bayer Inc. announced that Health Canada has issued a Notice of Compliance (NOC) expanding the approved indication for LYNKUET (elinzanetant) to include the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with adjuvant endocrine therapy (AET) for breast cancer.
• In August 2026, AbCellera announced positive topline results from the Phase 2 segment of its Phase 1/2 clinical trial evaluating ABCL635, an investigational antibody targeting the neurokinin 3 receptor (NK3R). 
• In February 2026, Astellas announced topline results from the STARLIGHT 2 Phase III pivotal trial for fezolinetant in Japan, an investigational oral, nonhormonal compound being studied for the treatment of vasomotor symptoms associated with menopause, which met the primary endpoint.
• In November 2025, Noema Pharma reported positive Phase IIa results from an open-label study evaluating cendifensine for vasomotor symptoms associated with menopause, demonstrating significant reductions in the frequency and severity of moderate-to-severe vasomotor symptoms compared with baseline.

Vasomotor Symptoms Epidemiology Segmentation

The vasomotor symptoms epidemiology section provides insights into the historical and current vasomotor symptoms patient pool and forecasted trends for the leading markets. In the US, among women aged ≥65 years, 20.9-45.1% reported vasomotor symptoms; 2.0% reported severe symptoms, and 17.6% reported moderate symptoms. 

The vasomotor symptoms treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Prevalent Vasomotor Symptoms Cases 
• Diagnosed Vasomotor Symptoms Prevalent Cases 
• Diagnosed Prevalent Vasomotor Symptoms Cases by Age 
• Diagnosed Vasomotor Symptoms Prevalent Cases by Severity 
• Vasomotor Symptoms Treated Cases

Scope of the Vasomotor Symptoms Market Report

• Vasomotor Symptoms Patient Population Forecast
• Vasomotor Symptoms Therapeutics Market Size
• Vasomotor Symptoms Pipeline Analysis
• Vasomotor Symptoms Market Size and Trends
• Vasomotor Symptoms Market Opportunity
• Vasomotor Symptoms Market Unmet Needs
• KOL's Views on Vasomotor Symptoms
• Vasomotor Symptoms Market Access and Reimbursement

Download the report to understand the recent developments in the vasomotor symptoms market @ Vasomotor Symptoms Clinical Trials

Table of Contents

Related Reports

Vasomotor Symptoms of Menopause Clinical Trial Analysis

Vasomotor Symptoms of Menopause Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vasomotor symptoms of menopause companies, including Mithra Pharmaceuticals, Acer Therapeutics, QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, and others.

Menopause Market

Menopause Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key menopause companies, including Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others.

Hot Flashes Market

Hot Flashes Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, and others.

Hot Flashes Clinical Trial Analysis

Hot Flashes Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

www.delveinsight.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vasomotor-symptoms-market-poised-for-growth-through-2036-driven-by-rising-adoption-of-hormonal-and-non-hormonal-therapies--delveinsight-302893845.html

SOURCE DelveInsight Business Research, LLP